PTEN, Insulin Resistance and Cancer
Related Experiment Video
Updated: Feb 27, 2026
Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Aiqing Li1, Minzi Qiu1, Hongbo Zhou2
1State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background:
The tumor suppressor PTEN serves as a negative regulator of PI3K/PTEN/Akt signaling pathway that regulates cellular functions such as cell growth, differentiation, proliferation and migration. The PI3K/PTEN/Akt signaling cascades might also have effect on glucose uptake via translocation of GLUT-4. Insulin controls energy storage and the whole body glucose homeostasis. Its binding to insulin receptor on the surface of diverse cells allows glucose entry into cells, and activates a variety of cellular actions. Insulin resistance is a common metabolic feature and established risk factor of many diseases. Its fundamental principle is inability of insulin to exert its normal metabolic effects, and nutrient imbalance and abnormal lipid accumulation in skeletal muscle, liver and adipose tissues.
Methods:
We review the literature on the structure and function of PTEN and its involvement in insulin resistance and tumor regulation, and summarized the detailed scientific achievements on this topic.
Results:
Suppressing PTEN expression plays a role in pro- or anti-inflammatory state during insulin resistance associated with obesity. Selective disruption of PTEN in pancreatic α-cells demonstrates that a lack of PTEN reduces circulating glucagon levels and protects against hyperglycemia and insulin resistance in high-fat diet-fed mice. Loss-of-function PTEN mutations in adipose tissue results in systemic glucose tolerance and insulin sensitivity improvement because of ascended recruitment of the GLUT-4 towards the membrane. Targeting tissuespecific PTEN deletion improves insulin sensitivity and protects from systemic insulin resistance. PTEN, as an important tumor suppressor gene, is frequently deleted or mutated in a variety of human tumors. Inactivation of PTEN by loss-of-function mutations leads to deregulated hyperproliferation of cells, leading to oncogenic transformation.
Conclusion:
Considering PTEN's important role in insulin resistance and tumor regulation, targeting the PTEN gene and/or protein will likely provide an efficient strategy for therapeutic intervention in cancer and metabolic diseases like type 2 diabetes mellitus, obesity, and cardiovascular dysfunction.
Insights
Targeting the PTEN gene offers a dual therapeutic strategy for both cancer and metabolic diseases. Modulating PTEN impacts insulin resistance, glucose homeostasis, and tumor suppression, paving the way for novel treatments.
Area of Science:
- Molecular Biology
- Metabolic Diseases
- Oncology
Background:
- PTEN (Phosphatase and tensin homolog) is a tumor suppressor regulating the PI3K/PTEN/Akt pathway, crucial for cell growth, migration, and glucose uptake via GLUT-4 translocation.
- Insulin resistance, a hallmark of metabolic diseases, involves impaired insulin signaling, leading to nutrient imbalance and ectopic lipid accumulation.
- PTEN's role extends to cellular functions, impacting energy storage and glucose homeostasis, making it a key player in metabolic regulation.
Purpose of the Study:
- To review the literature on PTEN's structure, function, and its dual role in insulin resistance and tumor regulation.
- To summarize scientific findings on PTEN's involvement in metabolic and oncogenic pathways.
- To explore therapeutic potential of targeting PTEN for cancer and metabolic disorders.
Main Methods:
- Comprehensive literature review on PTEN's structure and function.
- Analysis of PTEN's involvement in insulin resistance mechanisms.
- Examination of PTEN's role in tumor suppression and oncogenesis.
Main Results:
- PTEN suppression influences inflammatory states in obesity-associated insulin resistance.
- PTEN disruption in pancreatic alpha-cells reduces glucagon, improving hyperglycemia and insulin resistance in mice.
- Loss-of-function PTEN mutations enhance glucose tolerance and insulin sensitivity by increasing GLUT-4 membrane recruitment.
Conclusions:
- Targeting PTEN offers a promising therapeutic strategy for cancer due to its tumor suppressor functions.
- PTEN modulation presents an efficient approach for treating metabolic diseases such as type 2 diabetes, obesity, and cardiovascular dysfunction.
- Dual targeting of PTEN gene/protein could address both oncogenic transformation and metabolic dysregulation concurrently.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
01:28Insulin: The Receptor and Signaling Pathways
01:19Psychoneuroimmunology: Diabetes and Cancer
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...